Atlantic Union Bankshares Corp Sells 830 Shares of Medtronic Plc (NYSE:MDT)
Atlantic Union Bankshares Corp Sells 830 Shares of Medtronic Plc (NYSE:MDT)
Atlantic Union Bankshares Corp reduced its stake in shares of Medtronic plc (NYSE:MDT – Get Rating) by 1.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 77,822 shares of the medical technology company's stock after selling 830 shares during the period. Atlantic Union Bankshares Corp's holdings in Medtronic were worth $6,984,000 at the end of the most recent reporting period.
大西洋聯合銀行股份有限公司最近提交給美國證券交易委員會的文件顯示,該公司在第二季度減持了美敦力股份(紐約證券交易所代碼:MDT-GET評級)1.1%。在此期間出售了830股後,該公司持有這家醫療技術公司77,822股股票。在最近一次報告期結束時,大西洋聯合銀行持有的美敦力股份價值6984,000美元。
Other institutional investors and hedge funds have also recently modified their holdings of the company. Chase Investment Counsel Corp raised its position in Medtronic by 2.9% during the 1st quarter. Chase Investment Counsel Corp now owns 3,220 shares of the medical technology company's stock worth $357,000 after buying an additional 90 shares during the last quarter. Wedge Capital Management L L P NC increased its holdings in shares of Medtronic by 3.6% during the 1st quarter. Wedge Capital Management L L P NC now owns 2,633 shares of the medical technology company's stock valued at $292,000 after purchasing an additional 92 shares in the last quarter. Main Street Financial Solutions LLC increased its holdings in shares of Medtronic by 0.9% during the 1st quarter. Main Street Financial Solutions LLC now owns 9,944 shares of the medical technology company's stock valued at $1,103,000 after purchasing an additional 92 shares in the last quarter. Rosenberg Matthew Hamilton increased its holdings in shares of Medtronic by 7.9% during the 1st quarter. Rosenberg Matthew Hamilton now owns 1,286 shares of the medical technology company's stock valued at $143,000 after purchasing an additional 94 shares in the last quarter. Finally, Riverwater Partners LLC increased its holdings in shares of Medtronic by 2.2% during the 1st quarter. Riverwater Partners LLC now owns 4,527 shares of the medical technology company's stock valued at $502,000 after purchasing an additional 99 shares in the last quarter. 79.81% of the stock is owned by institutional investors.
其他機構投資者和對衝基金最近也調整了對該公司的持股。大通投資顧問公司(Chase Investment Counsel Corp)在第一季度將其在美敦力的頭寸提高了2.9%。大通投資顧問公司(Chase Investment Counsel Corp)目前持有這家醫療技術公司3,220股股票,價值357,000美元,此前該公司在上個季度又購買了90股。韋奇資本管理公司L L P NC在第一季度增持了3.6%的美敦力股票。Wdge Capital Management L L P NC現在擁有這家醫療技術公司2,633股股票,價值29.2萬美元,此前在上個季度又購買了92股。Main Street Financial Solutions LLC在第一季度增持了0.9%的美敦力股票。Main Street Financial Solutions LLC在上個季度又購買了92股後,現在擁有9944股這家醫療技術公司的股票,價值1,103,000美元。羅森博格馬修·漢密爾頓在第一季度增持了7.9%的美敦力股票。羅森博格·馬修·漢密爾頓現在擁有這家醫療技術公司1,286股股票,價值143,000美元,上個季度又購買了94股。最後,Riverwater Partners LLC在第一季度增持了2.2%的美敦力股票。Riverwater Partners LLC現在擁有這家醫療技術公司4527股股票,價值50.2萬美元,上個季度又購買了99股。79.81%的股票由機構投資者持有。
Analyst Upgrades and Downgrades
分析師升級和下調評級
MDT has been the topic of a number of research analyst reports. Raymond James cut shares of Medtronic from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 24th. Wolfe Research started coverage on shares of Medtronic in a research note on Tuesday, July 5th. They set an "underperform" rating and a $85.00 target price on the stock. Piper Sandler lowered their target price on shares of Medtronic from $100.00 to $90.00 in a research note on Tuesday, August 23rd. Truist Financial lowered their target price on shares of Medtronic from $111.00 to $97.00 and set a "hold" rating on the stock in a research note on Wednesday, July 20th. Finally, Stifel Nicolaus lowered their target price on shares of Medtronic from $125.00 to $105.00 in a research note on Monday, July 18th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Medtronic presently has an average rating of "Hold" and an average price target of $111.52.
MDT已經成為許多研究分析師報告的主題。8月24日,雷蒙德·詹姆斯在一份研究報告中將美敦力的股票評級從“跑贏大盤”下調至“市場表現”。Wolfe Research在7月5日星期二的一份研究報告中開始報道美敦力的股票。他們為該股設定了“表現不佳”的評級和85.00美元的目標價。派珀·桑德勒在8月23日週二的一份研究報告中將美敦力的目標股價從100.00美元下調至90美元。7月20日,Truist Financial在一份研究報告中將美敦力股票的目標價從111.00美元下調至97.00美元,並將該股的評級設定為持有。最後,Stifel Nicolaus在7月18日星期一的一份研究報告中將美敦力的目標股價從125.00美元下調至105.00美元。一名分析師對該股的評級為賣出,11名分析師給出了持有評級,8名分析師給出了該公司的買入評級。根據MarketBeat.com的數據,美敦力目前的平均評級為“持有”,平均目標價為111.52美元。
Medtronic Stock Performance
美敦力股票表現
Medtronic (NYSE:MDT – Get Rating) last announced its quarterly earnings results on Tuesday, August 23rd. The medical technology company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.01. The business had revenue of $7.37 billion during the quarter, compared to analysts' expectations of $7.20 billion. Medtronic had a return on equity of 13.64% and a net margin of 16.75%. During the same quarter last year, the business posted $1.41 earnings per share. As a group, analysts expect that Medtronic plc will post 5.53 EPS for the current fiscal year.
美敦力(紐約證券交易所代碼:MDT-GET評級)最近一次公佈季度收益是在8月23日,星期二。這家醫療技術公司公佈本季度每股收益為1.13美元,比分析師普遍預期的1.12美元高出0.01美元。該業務當季營收為73.7億美元,高於分析師預期的72億美元。美敦力的股本回報率為13.64%,淨利潤率為16.75%。去年同一季度,該公司公佈的每股收益為1.41美元。分析師預計,作為一個整體,美敦力本財年每股收益將達到5.53歐元。
Medtronic Dividend Announcement
美敦力股息公告
The business also recently declared a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Friday, September 23rd will be given a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.30%. The ex-dividend date is Thursday, September 22nd. Medtronic's dividend payout ratio (DPR) is presently 70.28%.
該公司最近還宣佈了季度股息,將於10月14日(星期五)支付。9月23日(星期五)登記在冊的投資者將獲得每股0.68美元的股息。這意味着年化股息為2.72美元,收益率為3.30%。除息日期為9月22日(星期四)。美敦力的股息支付率(DPR)目前為70.28%。
About Medtronic
美敦力簡介
(Get Rating)
(獲取評級)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
美敦力開發、製造和銷售基於設備的醫療療法,面向世界各地的醫療系統、醫生、臨牀醫生和患者。其心血管產品組合提供植入式心臟起搏器、心律轉復除顫器和心臟再同步治療設備;心臟消融產品;可插入式心臟監測系統;TYRX產品;以及遠程監測和以患者為中心的軟件。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Medtronic (MDT)
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免費獲取StockNews.com關於美敦力(MDT)的研究報告
- 這是買入美光科技的難忘時刻
- 雷神工業走出谷底
- 讓Paychex股票為您努力工作
- 利潤下降對CarMax價值主張的挑戰
- Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何?
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
接受美敦力日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對美敦力及相關公司評級的每日摘要。